LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), ...

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can't control symptoms using topical prescription ...

Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

“With a similar mechanism of action, as well as demonstrated efficacy and safety, Ebglyss is expected to capture market share ...

and Adbry ® (tralokinumab-ldrm) in the treatment of patients 12 years of age or older with moderate to severe atopic dermatitis (AD). The findings are being presented across 18 posters at the ...

It is also approved for adults in the US under the tradename Adbry. Vice president and general manager of UK & Ireland at LEO Pharma, Sarah Kleinpeter, said: “We are pleased that adolescents ...

26 A late-breaking presentation will also be presented for Adtralza/Adbry, highlighting the interim real-world effectiveness results of tralokinumab in adult patients with head and neck atopic ...

Credit: LEO pharmaceuticals. Tralokinumab-ldrm is a full human IgG4 monoclonal antibody that specifically binds to the IL-13 cytokine. Over 66% of patients achieved an IGA score of 0 or 1 and EASI ...

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin ...

1 Tralokinumab-ldrm is marketed in the U.S. as Adbry for patients 12 years of age or older with moderate to severe AD whose disease is not adequately controlled with topical prescription therapies ...